They won't be angry. We'd love to move faster and get it right out to patients. FDA told us not to and made an example of CYDY to show what happens to the disobedient. They literally denied approval of Leronlimab to spite CYDY's unruly behavior. That's not going to happen with IPIX.
You may also find page 9 to be of interest. It may explain why the company initially stated there would be an interim report, but has since abstained:
FDA strongly discourages disseminating data from ongoing trials. Knowledge of accumulating data by trial investigators and patients can adversely affect patient accrual, adherence, and retention, as well as endpoint assessment, compromising the ability of the trial to reliably achieve its objective in a timely manner.
News 
Market Data 
Discover 
